Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors (NCT05176483)
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology or Other Agents in Subjects With Unresectable Advanced or Metastatic Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alone, and in combination with nivolumab (doublet), nivolumab + ipilimumab (triplet) and nivolumab + relatlimab (triplet) and in combination with docetaxel and prednisone in participants with advanced solid tumors. In addition, the study will evaluate the effect of multiple dose administration of zanzalintinib on the single-dose pharmacokinetics of sensitive CYP3A4, CYP2C9, CYP2C19, or CYP1A2 substrates in participants with advanced solid tumors. In the Expansion Stage, the safety and efficacy of zanzalintinib as monotherapy and in combination therapy will be further evaluated in tumor-specific Expansion Cohorts.
Who can join: Review the eligibility criteria below.
Location: Exelixis Clinical Site #67 — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (122 Sites)
Showing the first 25 of 122 sites.
- Exelixis Clinical Site #67 — Phoenix, Arizona
- Exelixis Clinical Site #1 — Tucson, Arizona
- Exelixis Clinical Site #123 — Palo Alto, California
- Exelixis Clinical Site #59 — Santa Barbara, California
- Exelixis Clinical Site #87 — Littleton, Colorado
- Exelixis Clinical Site #62 — New Haven, Connecticut
- Exelixis Clinical Site #49 — Newark, Delaware
- Exelixis Clinical Site #48 — Celebration, Florida
- Exelixis Clinical Site #11 — Gainesville, Florida
- Exelixis Clinical Site #78 — Jacksonville, Florida
- Exelixis Clinical Site #47 — Miami, Florida
- Exelixis Clinical Site #61 — Plantation, Florida
- Exelixis Clinical Site #8 — Tampa, Florida
- Exelixis Clinical Site #26 — Chicago, Illinois
- Exelixis Clinical Site #4 — Indianapolis, Indiana
- Exelixis Clinical Site #122 — Louisville, Kentucky
- Exelixis Clinical Site #14 — Baltimore, Maryland
- Exelixis Clinical Site #7 — Boston, Massachusetts
- Exelixis Clinical Site #65 — Detroit, Michigan
- Exelixis Clinical Site #13 — Detroit, Michigan
- Exelixis Clinical Site #68 — Rochester, Minnesota
- Exelixis Clinical Site #2 — Omaha, Nebraska
- Exelixis Clinical Site #5 — Omaha, Nebraska
- Exelixis Clinical Site #55 — Las Vegas, Nevada
- Exelixis Clinical Site #88 — East Brunswick, New Jersey
📞 Contact the Study Coordinator
Phone: 1-888-EXELIXIS (888-393-5494)
Email: druginfo@exelixis.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Renal Cell Carcinoma (RCC)
- A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) — Los Angeles, California
- Ablative Radioembolization of Renal Cell Carcinoma Trial — London, Ontario
- Investigation of Lymph Node Biology in Kidney Cancer — New Haven, Connecticut
- Comparing Two Weight Loss Programs for the Prevention of Kidney Cancer Progression Among Patients With Small Renal Masses on Active Surveillance — Buffalo, New York
Explore by condition: All Renal Cell Carcinoma (RCC) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.